- 1. A product comprising a CCH-A subunit isolated from hemocyanin of the marine gastropod *Concholepas concholepas*, wherein the CCH-A subunit has a molecular weight of about 404 kDa, is stable in the absence of Ca<sup>+2</sup> and Mg<sup>+2</sup> and is at least 95% pure.
- 2. The use of the product according to claim 1 as an immunostimulant agent in the innate or adaptive vertebrates response, or as immunotherapeutic agent in cancer or tumors of either humans or animals.

## 3. A composition comprising:

- a. a product comprising a CCH-A subunit isolated from hemocyanin of the marine gastropod *Concholepas concholepas*, wherein the CCH-A subunit has a molecular weight of about 404 kDa, is stable in the absence of Ca<sup>+2</sup> and Mg<sup>+2</sup> and is at least 95% pure, and
  - b. a physiologically acceptable isotonic buffer.
- 4. The composition according to claim 3, wherein the composition further comprises an other protein, an LPS, a polysaccharide, or an other hemocyanin or a subunit thereof.
- 5. The composition according to claim 4, wherein the other hemocyanin comprises a CCH-B subunit.
- 6. A method for treating a disease state selected from bladder cancer, melanoma, mammary cancer or ovary cancer, comprising the step of administering to a patient with the disease state an effective anti-tumor amount of a composition comprising:
- a. a product comprising a CCH-A subunit isolated from hemocyanin of the marine gastropod *Concholepas concholepas*, wherein the CCH-A subunit has a molecular weight of about 404 kDa, is stable in the absence of Ca<sup>+2</sup> and Mg<sup>+2</sup> and is at least 95% pure, and
  - b. a physiologically acceptable isotonic buffer.

7. A method according to Claim 6 wherein the composition further comprises an other protein, an LPS, a polysaccharide, or an other hemocyanin or a subunit thereof.

.

- 8. The method according to Claim 7 wherein the other hemocyanin comprises a CCH-B subunit.
- 9. The method according to Claim 6, wherein the composition comprises a concentration of CCH-A subunit from about 0.1 mg/ml to 20 mg/ml.
- 10. The method according to Claim 9, wherein the concentration of CCH-A subunit is from about 2 to 10 mg/ml.
- 11. The method according to Claim 10, wherein the concentration of CCH-A subunit is 5 mg/ml
- 12. The method of Claim 8, wherein the CCH-A subunit forms a heterodimer with the CCH-B subunit.
- 13. A method for enhancing the immunogenicity of a hapten or peptide, comprising the step of administrating with the hapten or peptide an amount of a product comprising a CCH-A subunit isolated from hemocyanin of the marine gastropod *Concholepas concholepas*, wherein the CCH-A subunit has a molecular weight of about 404 kDa, is stable in the absence of Ca<sup>+2</sup> and Mg<sup>+2</sup>, and is at least 95% pure, and wherein the product is an immunogen.
- 14. The method according to claim 13, wherein the CCH-A subunit is a carrier for the hapten or peptide.
- The method according to claim 13, wherein the CCH-A subunit is an adjuvant.
- 16. The method according to claim 13, wherein the CCH-A subunit is linked to the hapten or peptide.

- 17. The method according to Claim 13, further comprising the step of administering another protein.
- 18. The method according to Claim 14, further comprising the step of administering another protein.
- 19. The method according to Claim 13, wherein the product further comprises a CCH-B subunit.
- 20. The method according to Claim 19 wherein the CCH-A subunit forms a heterodimer with the CCH-B subunit.